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Screening for Adenocarcinoma of the Prostate 
Brian J. Miles, MD* 
Adenocarcinoma of the prostate is the second leading cause of cancer and the third leading cause of death from cancer 
in American men. For American black men it is the number one 
cause of cancer and death from cancer. The clinical incidence of 
carcinoma of the prostate is approximately 69 per 100,000 men, 
but the prevalence is between 5% to 40% of men over age 50 (1). 
Certainly this makes cancer of the prostate the most prevalent 
cancer in males. Unfortunately, over half of the patients present-
ing with this disease have either significant locally advanced or 
metastatic disease. 
The need for a screening method for cancer of the prostate has 
been recognized for some time and was advocated as early as 
1905 by Young (2). However, great care must be exercised when 
evaluating the value of any potential screening test. It is far too 
easy to become optimistic based on seemingly high sensitivity 
and specificity values for a given test. The true usefulness of any 
testing modality lies in its "predictive value" (3). Given that a 
particular test is positive, the probability that the patient actually 
has prostate cancer is its predictive value: 
Sensitivity = 
#TP + FN 
Specificity = #TN 
#TN + FP 
Predictive Value Positive S X P 
(S X P) -I- ([1 - SP] X [1 - P]) 
where TP = true positives, FN = false negatives, TN = true 
negatives, FP = false positives, S = sensitivity, P = preva-
lence, and SP = specificity. 
Unfortunately, predictive value is seldom referred to when-
ever the subject of screening is broached. In prostate cancer, if 
predictive values were used they would be questionable because 
of the large discrepancy between the prevalence of the disease 
and its clinical incidence. Since only one third of the patients 
with prostate cancer will ever manifest the disease clinically, the 
question is raised as to whether or not we will be screening pa-
tients, at considerable expense, who do not need treatment. This 
issue is beyond the scope of this brief review but has been 
reviewed elsewhere (4). 
If we accept "prevalence" as being in the 5% to 40% range, 
the predictive value of most modalities discussed herein is still 
not high enough to warrant their consideration as screening 
tools. In fact, the American Urologic Association (AUA) re-
cently published a directive strongly discouraging the use 
of prostate specific antigen (PSA) and prostate ultrasound 
as screening modalities (5). However, these modalities as well 
as others are available for the evaluation of adenocarcinoma of 
the prostate. 
Creatine Kinases/Alkaline Phosphatase 
Since Gutman and Gutman (6) discovered the association 
between acid phosphatase and adenocarcinoma of the pros-
tate, investigators have been looking for a prostate serum 
marker. Potential serum markers that have been evaluated in 
the past years include creatine kinase, alkaline phosphatase, 
ribonuclease, lactate dehydrogenase isoenzymes, hy-
droxyproline, polyamines, alfa-fetoprotein, and beta human 
chorionic gonadotropin, among others. The best, according 
to Fair et al (7), is creatine kinase. This is an enzyme that cat-
alyzes the transfer of a phosphate group from phos-
phocreatine to adenosine diphosphate. There are three bands 
of creatine kinase. The BB band is found exclusively in the 
genitourinary system, especially in the cytoplasm of normal 
and cancerous prostate tissue. Unfortunately, the sensitivity 
is less than 15% and the specificity is approximately 45% in 
large clinical trials. Therefore, creatine kinase has limited 
value for following patients with known carcinoma of the 
prostate and is of no value as a screening tool. The alkaline 
phosphatase test has similar problems with sensitivity and 
specificity and is of value only for following response to ther-
apy in patients with known disease. 
Acid Phosphatase 
The acid phosphatases have been the mainstay of serum mark-
ers for evaluation of prostate carcinoma since the 1930s when 
they were discovered by Gutman and Gutman (6). Acid phos-
phatase is an enzyme that hydrolyzes phosphate esters at a PH of 
< 7.0. They are ubiquitous, being found in serum, red and 
white blood cells, the spleen, kidney, bone, and numerous other 
organs such as the prostate. In the prostate acid phosphatase is 
found in the lysosomal fraction of epithelial cells. Its concentra-
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don in the prostate is 1,000 times greater than that of any other 
organ or cell. Of the nine isoenzymes of acid phosphatase, iso-
enzyme 2 has the greatest activity in the prostatic acid phos-
phatase test. Semen is the only tissue fluid with isoenzyme 
2 activity. 
When the prostate becomes cancerous it retains its ability to 
produce acid phosphatase, although the overall tissue concentra-
tions are reduced, as measured by qualitative histochemical 
studies. There is a circadian rhythm found in the serum levels of 
acid phosphatase in patients with cancer of the prostate but not in 
normal patients, necessitating repeated measurements in follow-
ing patients with known prostate carcinoma. 
Prostatic acid phosphatase (PAP) is assayed by numerous 
methods including enzymatic studies, radioimmunoassays 
(RIAs), counterimmunoelectrophoresis, enzyme-linked immu-
nosorbent assay, and fluorescent immune antibodies. Much con-
troversy existed in the 1970s regarding RIA versus enzymatic 
studies. However, numerous investigators found significant 
problems with the specificity and sensitivity of both methods 
(8-12). The enzymatic method of detecting acid phosphatase is 
very specific but not very sensitive, and the RIA is very sensitive 
but much less specific (13). Bruce et al (9) and Cooper and 
Finkle (14) confirmed that acid phosphatase levels as determined 
by either enzymatic or RIA methods are not effective in dis-
tinguishing between benign prostatic hypertrophy (BPH) and 
localized adenocarcinoma of the prostate. Therefore, the acid 
phosphatases have no value as screening tests. Acid phosphatase 
has much more value for following patients with known disease 
to evaluate their response to therapy or to predict disease 
progression. 
Prostate Specific Antigen 
Discovered by Wang et al (15) in 1979, PSA is a relatively new 
marker for evaluating patients with adenocarcinoma of the pros-
tate. Its concentration is similar in normal, benign, and malig-
nant tissue. This secretory-like protein is found in the seminal 
fluid and is a small molecule but highly inmiunogenic. It is en-
tirely different from PAP, and with it either polyclonal or mono-
clonal antisera are easily generated. PSA is not prostate cancer 
specific; it is prostate tissue specific. 
PSA is an excellent marker for evaluating patients with known 
adenocarcinoma of the prostate, but, as with acid phosphatase, 
false elevations occur in patients with BPH and "falsely" nor-
mal levels may be obtained in patients with known prostate car-
cinoma. Ban et al (16) found elevated PSA levels in only 25% of 
patients with known carcinoma. Stamey et al (17) recently re-
ported that BPH contributed an average serum level of 0.3 ng/ 
mL per gram of prostate tissue resected. While this value may be 
high, others have found that approximately 20% of patients with 
BPH have elevated PSA levels (18-20). As with PAP, the value of 
PSA is in following patients with known carcinoma. PSA 
should not be utilized as a screening tool. The AUA recently 
made the following statement on PSA (5): 
Serum PSA is not effective as a screening test for prostate 
cancer At present, semm PSA appears to be most useful 
for determining the presence of residual cancer after 
abladve surgical procedures and determining early recur-
rence following radiation therapy, radical surgery, or hor-
monal therapy. Further study will be required to define 
other roles of PSA in prostate cancer patients. 
Other Modalities 
There are no radiographic studies suitable to use as screening 
modalities for carcinoma of the prostate. However, the recent 
development of prostatic ultrasound has raised the hope that it 
may be useful in this way. Perhaps prostatic ultrasound may be-
come as valuable as the mammogram in females. However, the 
high cost of this test and the low clinical incidence of prostate 
carcinoma make its usefulness questionable. According to the 
AUA (5): 
Transrectal prostatic ultrasonography, because of its rela-
tive lack of specificity and sensitivity, cannot be recom-
mended for mass screening for carcinoma of the prostate 
in asymptomatic male patients. 
Transrectal ultrasonography is not recommended for 
routine use in the patient who has no symptoms to suggest 
prostatic carcinoma, no physical findings of prostatic car-
cinoma, and/or no laboratory or radiographic evidence of 
prostatic carcinoma. 
Aspiration cytology and random core needle biopsies of the 
prostate could be effective screening tools. However, because of 
the invasive nature and possible complications of these tests, 
they cannot be used for large-scale unselected population 
screening (21). 
The digital rectal examination is currently the most effective 
screening tool for adenocarcinoma of the prostate. In evaluating 
the rectal examination as a screening test for adenocarcinoma of 
the prostate, Thompson et al (22) found that screened patients 
were discovered at an earlier clinical stage (stage B) than un-
screened patients (70% versus 40%, although pathologic down-
staging lowered this to 43% versus 28%). As determined by 
McNeal et al (23), we can nuss as many as 25% of the padents 
with adenocarcinoma of the prostate due to the anterior origin of 
this disease. Thus a high index of suspicion and thorough rectal 
examination are extremely important. The rectal examinadon is 
easy to perform, can be done by all physicians, and therefore 
remains the gold standard in screening for prostate carcinoma 
(24). 
Guinan et al (25) compared five tests for the diagnosis of ade-
nocarcinoma ofthe prostate: aspiration cytology, prostatic ultra-
sound, acid phosphatase, PSA, and rectal examination. Not the 
most rigorous of studies, their results are probably unfairiy 
biased against prostatic ultrasound since the transducer used was 
only 3'/2 to 4 MHz, well below the capacity of transducers cur-
rently in use. The study included 280 men, mean age 68.1 years, 
who underwent a transrectal biopsy. Of these patients, 28 had 
histologic diagnosis of adenocarcinoma of the prostate. The re-
sults ofthe study permitted calculation of relative sensitivity and 
specificity values for each modality. The authors developed an 
"efficiency coefficient," defined as the percentage of patients 
correctly determined to have prostate cancer The formula uti-
lizes prevalence, sensitivity, and specificity: 
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(pa -b [1 - p]b) X 100 
where a = sensitivity, b = specificity, and p = prevalence (per-
centage of patients with carcinoma of the prostate in the popula-
tion studied). 
The efficiency coefficients were 63% for aspiration cytology, 
71% for prostatic ultrasound, 74% for PSA, 66% for acid phos-
phatase, and 75% for rectal examination. As evident from these 
data, the digital rectal examination was superior to all other 
modalities and is the least expensive of these tests. As more 
work is completed, prostatic ultrasound may surpass the digital 
rectal examination as a screening tool. However, primary care 
physicians and urologists should continue to trust a well-per-
formed rectal examination as an effective screening procedure 
for adenocarcinoma of the prostate (26). Patients should not be 
routinely subjected to PSA, PAP, aspiration biopsy, or ultrasonic 
testing until the predictive values of these tests become much 
higher. 
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